Related Experiment Video
Updated: Sep 14, 2025
Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
Published on: January 12, 2024
Oxymatrine for treating atopic dermatitis: Network pharmacology, bioinformatics, metabolomics, and experimental
Jin Huang1, Hongxia Li2, Jiqiang Liang2
1Shenzhen Pingle Orthopedic Hospital (Shenzhen Pingshan Traditional Chinese Medicine Hospital), Shenzhen 518001, China; State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
Background:
Sophora flavescens Aiton is among the most used herbs for atopic dermatitis (AD). However, the therapeutic effect of oxymatrine (OMT), one of the main active components of Sophora flavescens Aiton, on AD and its mechanism of action remain unclear.
Methods:
To investigate the anti-AD effects of OMT, we used a Cavia porcellus model of AD induced by 2,4-Dinitrochlorobenzene (DNCB) or Ovalbumin (OVA). In both DNCB- and OVA-induced Cavia porcellus, we assessed the total dermatitis score and performed histopathology and evaluated immune cell factors to gauge the anti-AD activity. To further explore the mechanism of action of OMT in AD treatment, we combined bioinformatics and network pharmacology with plasma metabolomics analysis.
Results:
In DNCB-induced and OVA-induced Cavia porcellus, OMT showed potent anti-atopic activity, including reduction of AD-like skin lesions and inhibition of inflammatory cytokine expression. Metabolic profiles revealed significant changes in lipid, histidine, and glutathione metabolism, which are related to inflammation, during OMT treatment in AD. Through bioinformatics analysis and network pharmacology, we identified 12 common targets among the potential 489 CE-related genes, 2513 immunity-related genes, and 477 OMT targets. The enrichment analysis of GO and KEGG pathways for the common targets revealed that they were mainly enriched in the IL-2, IL-17, IL-10, IL-4, and IL-13 signaling pathways as well as pathways related to neutrophil degranulation and Th1 and Th2 cell differentiation. These signaling pathways are closely linked to mast cell degranulation. In the RBL-2H3 cell degranulation model, OMT inhibited the levels of inflammatory cytokines, β-hexosaminidase, histamine, and Ca2+levels in a dose-dependent manner.
Conclusions:
OMT inhibits mast cell degranulation and decreases the release of inflammatory factors, including histamine, LTB4, β-aminohexylglucosidase, IL-2, IL-4, and IL-13, for treating AD.
More Related Videos
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:24Cholinergic Antagonists: Pharmacokinetics
01:26Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...